RT Journal Article
SR Electronic
T1 Smoking and the risk of COVID-19 infection in the UK Biobank Prospective Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20092445
DO 10.1101/2020.05.05.20092445
A1 Cho, Eo Rin
A1 Jha, Prabhat
A1 Slutsky, Arthur S.
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.05.20092445.abstract
AB Several studies suggest a lower prevalence of smoking than expected among adults with coronavirus disease (COVID-19). We conducted logistic regression analyses of the UK Biobank prospective study of 0.5 million adults followed for an average of 11 years. Compared to women, men were more likely to be tested and to test positive. In sex-stratified analyses, current smokers had higher adjusted Odds Ratios (OR) for being tested (male OR 1.60, 95%CI 1.32-1.95 and female OR 1.50,1.21-.1.86). Current smokers were more slightly more likely than never smokers to test positive for COVID-19. Further examination of smoking as a risk factor for COVID-19 is required. These must take into account reverse causality, where smokers quit to avoid disease as well as prior diseases.Competing Interest StatementAS is a co-founder of a company that has developed a nicotine replacement product; this company is working with Phillip Morris International. ERC and PJ report no potential conflict of interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the UK Biobank are openly available.